Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Mosunetuzumab (Primary) ; Lenalidomide; Rituximab; Tocilizumab
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms Celestimo
- Sponsors Roche
- 11 Dec 2023 Results presented in a Roche media release.
- 12 Oct 2023 Planned number of patients changed from 400 to 474.
- 02 Jan 2023 Planned primary completion date changed from 1 May 2029 to 25 Aug 2025.